Ilaprazole sodium

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H17N4O2S.Na
Molecular Weight	388.419
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].COC1=CC=NC(C[S+]([O-])C2=NC3=CC=C(C=C3[N-]2)N4C=CC=C4)=C1C

InChI

InChIKey=ZQGDDMFDBZPGCD-UHFFFAOYSA-N

InChI=1S/C19H17N4O2S.Na/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23;/h3-11H,12H2,1-2H3;/q-1;+1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C19H17N4O2S
Molecular Weight	365.429
Charge	-1
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936 | https://www.ncbi.nlm.nih.gov/pubmed/11215326 | http://www.drugsupdate.com/generic/view/1243 | http://eng.dailypharm.com/News/news_view.html?ID=362 | https://www.ncbi.nlm.nih.gov/pubmed/28388576 | http://www.pharmalink.kr/detailinfo.php?code=20081068801

Ilaprazole or IY-81149 (2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl -5-(1H-pyrrol-1-yl)-1H-benzimidazole, CAS 172152-36-2) is a proton pump inhibitor. Ilaprazole revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole. Ilaprazole is approved in China and South Korea for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Recently it was discovered that ilaprazole inhibited the cancer growth by targeting T-cell-originated protein kinase (TOPK) both in vitro and in vivo.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/potassium-transporting ATPase 39 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11304936	Inhibitor 8297		6.0 µM [IC50]
PDZ-binding kinase 2 Target ID: CHEMBL4896 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576	Inhibitor 8297		111.0 µM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Colon cancer 62 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28388576	Primary	Preclinical	Unknown Approved Use Unknown
Gastroesophageal reflux disease 59 Sources: http://adisinsight.springer.com/drugs/800010706	Primary	Approved 8429	Noltec Approved Use Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date 1.19111038E12
Peptic ulcer 72 Sources: http://adisinsight.springer.com/drugs/800010706	Primary	Approved 8429	Noltec Approved Use Ilaprazole is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Launch Date 1.19111038E12

PubMed

Title	Date	PubMed
Comparison of IY81149 with omeprazole in rat reflux oesophagitis.	2000 Oct-Dec	11350494
The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.	2014 Sep	25041486
Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase.	2017 Jun 13	28388576

Patents

Sample Use Guides

In Vivo Use Guide

Short-term treatment of duodenal ulcer: Normally, 10 mg of adult is administered orally once a day. It is usually administered for up to 4 weeks. Short-term treatment of gastric ulcer: Normally, an adult dose of 10 mg is orally administered once a day. It is usually administered for 4 to 6 weeks. This medicine should be swallowed with water 1 hour before meals and should not be chewed or crushed. The recommended adult dosage of Ilaprazole is 5-20 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Ilaprazole exhibited potent inhibitory activities against the growth of HCT116 cells (IC50 = 40 uM) and ES-2 cells (IC50 = 33.2 uM). Ilaprazole (100 and 50 uM) induces apoptosis in ES-2 and HCT116 cells.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 19:09:54 UTC 2023` Edited by `admin` on `Sat Dec 16 19:09:54 UTC 2023`
Record UNII	T8KRT8S6GR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Ilaprazole sodium

Common Name

English

SODIUM ILAPRAZOLE

Common Name

English

Ilaprazole sodium [WHO-DD]

Common Name

English

1H-Benzimidazole, 2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-(1H-pyrrol-1-yl)-, sodium salt (1:1)

Systematic Name

English

1H-Benzimidazole, 2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(1H-pyrrol-1-yl)-, sodium salt

Systematic Name

English

Code System Code Type Description

PUBCHEM

53353154

Created by admin on Sat Dec 16 19:09:54 UTC 2023 , Edited by admin on Sat Dec 16 19:09:54 UTC 2023

PRIMARY

CAS

172152-50-0

Created by admin on Sat Dec 16 19:09:54 UTC 2023 , Edited by admin on Sat Dec 16 19:09:54 UTC 2023

PRIMARY

FDA UNII

T8KRT8S6GR

Created by admin on Sat Dec 16 19:09:54 UTC 2023 , Edited by admin on Sat Dec 16 19:09:54 UTC 2023

PRIMARY

Related Record Type Details


					776Q6XX45J

ILAPRAZOLE

PARENT -> SALT/SOLVATE

Amount:

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Launch Date

Approved Use

Launch Date

PubMed

Patents

Sample Use Guides